公司資料
Immunovant 股價、新聞與催化劑
- 股票代碼:
- IMVT
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
37.65 USD (+3.49%)
收盤價
最後更新: 2026年9月17日
6.35B USD
市值
股價為何變動
截至 2026年9月17日，IMVT 上漲 3.49%，收於 $37.65。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
Immunovant is an immunology company focused on FcRn inhibition for autoantibody-driven diseases.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, Immunovant sits in clinical-stage autoimmune biotechnology.
商業模式特徵
Its model is built around proof-of-concept data, dose optimization, and the potential to expand into multiple antibody-mediated diseases.
生技產業定位
Immunovant is a catalyst-heavy immunology name whose stock reacts to clinical differentiation and platform confidence.
未來催化劑
- Immunovant is heading into a more important stretch around IMVT-1402. Management's latest framing highlights Recent Highlights and Upcoming Milestones: The Company announced preliminary Week 16 (end of Period 1) results from the IMVT-1402 trial in D2T RA with ACR20, ACR50, and ACR70.... The stock is likely to react most to whether those milestones keep moving without a reset.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。